NY-Times: "But he is still hoping for one more successful investment — from a remaining, sizable stake in Intellect Neurosciences. The company has a market valuation of only $1.5 million. But Mr. Blech said that if a drug for Alzheimer’s disease showed some promise in animal testing, Intellect could be acquired for a much larger sum.
“If it works out, we’re out of trouble and I can pay my fines,” he said. “It’s about hanging on.”"